European Online Travel Champion obilet.com Ready for Record Growth
obilet.com, Turkey’s premier online travel ticketing platform, is set to enjoy rapid growth in the wake of the Covid-19 pandemic. Having just acquired its arch-rival Biletall, Obilet is forecast to sell more than 20 million tickets in 2021 – up from 8 million in 2020 – and close out the year with $300 million GMV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005055/en/
Having just acquired its arch-rival Biletall, Obilet is forecast to sell more than 20 million tickets in 2021, and close out the year with $300 million GMV. (Photo: Business Wire)
Thanks to its unique offerings and innovative business model, the Istanbul-based travel-tech firm is now poised to expand its geographic reach amid an expected post-Covid global recovery.
SaaS-Powered Business Model
Already known throughout the region for its enormously popular ticket-booking app, Obilet’s primary distinction lies in its SaaS (Software-as-a-Service) powered business model. Obilet, invested in by EarlyBird and EBRD, provides bus operators with a best-in-class Ticket Management System (TMS) featuring 24/7 technical support. The company thereby creates a “lock-in effect” for its business operations on the supply side.
By distributing its portfolio of bus operators using its SaaS to other online ticketing platforms on a revenue-sharing basis, Obilet adds additional revenue streams on top of its lucrative B2C sales.
One of the world’s top-10 platforms for online bus and flight tickets, obilet.com saw remarkable growth in the pre-Covid-19 2016-2019 period, boasting a compound annual growth rate (CAGR) of 77%.
Biletall Buyout Cements Leading Position
Earlier last month (July 12), Obilet cemented its regional position by acquiring Biletall, its chief B2C and B2B competitor, which since the 2000s had played a pioneering role in the digitalization of Turkey’s travel industry. Although Obilet stole the top spot from Biletall in 2016 on the B2C side, Biletall nevertheless retained its leading position at B2B coverage.
The acquisition will give Obilet 100% destination coverage in one of the world’s largest bus markets, and the biggest in Europe. Turkey’s intra-state bus market currently generates some 200 million ticket sales per year, corresponding to roughly $3 billion annually.
Currently, more than 300 bus operators compete in this highly fragmented market, which remains largely unconsolidated despite the 2019 acquisition of the country’s largest domestic bus operator by Flix.
Plans for Expansion in Post-Covid Era
Obilet now is equipped with plug-and-play B2B and SaaS solutions to be offered to both operators and online/offline ticket resellers in neighboring countries, where there is huge revenue potential for the Turkish start-up.
Obilet’s vastly enhanced market share, coupled with rising travel demand in the post-Covid era, is expected to yield 40 million ticket sales in 2022 and a GMV of over $500 million. Company officials even suggest that, as Obilet gradually expands into fresh markets, annual GMV could reach as much as $1 billion within the next few years.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005055/en/
Contact information
Ali Yılmaz
external.relations@obilet.com
+90 212 963 03 53
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release
Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release
Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release
AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by
illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom